Sarah C Moser

6PUBLICATIONS
58CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsCancer cell biologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

|Aug 13, 2025
NASP modulates histone turnover to drive PARP inhibitor resistance.

Sarah C Moser, Anna Khalizieva, Josef Roehsner

|Mar 03, 2025
Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

Sarah C Moser, Jos Jonkers

|May 31, 2023
FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks.

Abdelghani Mazouzi, Sarah C Moser, Federico Abascal

|Apr 07, 2023
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

Petra Ter Brugge, Sarah C Moser, Ivan Bièche

|Jul 21, 2021
Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

Mariana Paes Dias, Sarah C Moser, Shridar Ganesan

Pageof 1

Frequent Collaborators

6 joint publications

Jos Jonkers

2 joint publications

Marieke van de Ven

2 joint publications

Thijn R Brummelkamp

2 joint publications

Abdelghani Mazouzi